Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
Frontiers in Neuroscience
|
March 5, 2021
Rapid and Low Cost Manufacturing of Cuff Electrodes
Matthew T Flavin, Marek A Paul, Alexander S Lim, et al.
Pulmonary Pharmacology & Therapeutics
|
May 5, 2004
Effective attenuation of endotoxin-induced acute lung injury by 2,3-diacetyloxybenzoic acid in two independent animal models
David A Eiznhamer, Michael T Flavin, Gary J Jesmok, et al.
Antimicrobial Agents and Chemotherapy
|
April 17, 2001
Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects
T Creagh, J L Ruckle, D T Tolbert, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 5, 1999
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI
Z Q Xu, R W Buckheit, T L Stup, et al.
Antiviral Chemistry & Chemotherapy
|
February 29, 2000
Plant-derived and semi-synthetic calanolide compounds with in vitro activity against both human immunodeficiency virus type 1 and human cytomegalovirus
Z Q Xu, E R Kern, L Westbrook, et al.
Planta Medica
|
April 8, 1999
Antiviral activities of biflavonoids
Y M Lin, M T Flavin, R Schure, et al.
The Journal of Heart Transplantation
|
September 1, 1990
Selective T-cell depletion with Ox-38 anti-CD4 monoclonal antibody prevents cardiac allograft rejection in rats
T Flavin, J Shizuru, K Seydel, et al.
HIV Clinical Trials
|
December 26, 2002
Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers
David A Eiznhamer, Terri Creagh, Jon L Ruckle, et al.
Antimicrobial Agents and Chemotherapy
|
February 1, 2012
Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies
Marci L English, Christine E Fredericks, Nancy A Milanesio, et al.
Journal of Medicinal Chemistry
|
March 14, 1997
Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C)
D E Zembower, S Liao, M T Flavin, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
Frontiers in Neuroscience
|
March 5, 2021
Rapid and Low Cost Manufacturing of Cuff Electrodes
Matthew T Flavin, Marek A Paul, Alexander S Lim, et al.
Pulmonary Pharmacology & Therapeutics
|
May 5, 2004
Effective attenuation of endotoxin-induced acute lung injury by 2,3-diacetyloxybenzoic acid in two independent animal models
David A Eiznhamer, Michael T Flavin, Gary J Jesmok, et al.
Antimicrobial Agents and Chemotherapy
|
April 17, 2001
Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects
T Creagh, J L Ruckle, D T Tolbert, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 5, 1999
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI
Z Q Xu, R W Buckheit, T L Stup, et al.
Antiviral Chemistry & Chemotherapy
|
February 29, 2000
Plant-derived and semi-synthetic calanolide compounds with in vitro activity against both human immunodeficiency virus type 1 and human cytomegalovirus
Z Q Xu, E R Kern, L Westbrook, et al.
Planta Medica
|
April 8, 1999
Antiviral activities of biflavonoids
Y M Lin, M T Flavin, R Schure, et al.
The Journal of Heart Transplantation
|
September 1, 1990
Selective T-cell depletion with Ox-38 anti-CD4 monoclonal antibody prevents cardiac allograft rejection in rats
T Flavin, J Shizuru, K Seydel, et al.
HIV Clinical Trials
|
December 26, 2002
Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers
David A Eiznhamer, Terri Creagh, Jon L Ruckle, et al.
Antimicrobial Agents and Chemotherapy
|
February 1, 2012
Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies
Marci L English, Christine E Fredericks, Nancy A Milanesio, et al.
Journal of Medicinal Chemistry
|
March 14, 1997
Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C)
D E Zembower, S Liao, M T Flavin, et al.
Page
of 6